PT1513525E - Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico - Google Patents

Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico Download PDF

Info

Publication number
PT1513525E
PT1513525E PT03731333T PT03731333T PT1513525E PT 1513525 E PT1513525 E PT 1513525E PT 03731333 T PT03731333 T PT 03731333T PT 03731333 T PT03731333 T PT 03731333T PT 1513525 E PT1513525 E PT 1513525E
Authority
PT
Portugal
Prior art keywords
treatment
gerd
antagonists
mglur5 antagonists
glutamate receptor
Prior art date
Application number
PT03731333T
Other languages
English (en)
Portuguese (pt)
Inventor
Anders Lehmann
Jan Mattsson
Thomas M Stormann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1513525(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1513525E publication Critical patent/PT1513525E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT03731333T 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico PT1513525E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (1)

Publication Number Publication Date
PT1513525E true PT1513525E (pt) 2008-06-24

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03731333T PT1513525E (pt) 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico

Country Status (24)

Country Link
EP (1) EP1513525B1 (https=)
JP (2) JP4683920B2 (https=)
CN (1) CN100430056C (https=)
AT (1) ATE395059T1 (https=)
AU (1) AU2003241585B2 (https=)
BR (1) BR0311759A (https=)
CA (1) CA2489730C (https=)
CY (1) CY1107954T1 (https=)
DE (1) DE60320990D1 (https=)
DK (1) DK1513525T3 (https=)
ES (1) ES2304510T3 (https=)
IL (1) IL165138A0 (https=)
IS (1) IS7654A (https=)
MX (1) MXPA04012659A (https=)
NO (1) NO20050154L (https=)
NZ (1) NZ536559A (https=)
PL (1) PL372186A1 (https=)
PT (1) PT1513525E (https=)
RU (1) RU2324484C2 (https=)
SE (1) SE0201943D0 (https=)
SI (1) SI1513525T1 (https=)
UA (1) UA81627C2 (https=)
WO (1) WO2004000316A1 (https=)
ZA (1) ZA200409908B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
BRPI0507499A (pt) * 2004-02-18 2007-07-24 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
EP2468727A1 (en) * 2006-03-29 2012-06-27 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as MGLUR2 antagonists
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2320892A2 (en) 2008-06-30 2011-05-18 Novartis AG Combination products
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
JP2013529622A (ja) 2010-06-24 2013-07-22 ノバルティス アーゲー １ｈ−キナゾリン−２，４−ジオンの使用
KR20140003580A (ko) 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
CN103889427A (zh) 2011-09-07 2014-06-25 诺华股份有限公司 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用
CN105263492B (zh) 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
BR112015016992A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
BR112022005579A2 (pt) * 2019-11-05 2022-06-21 Claes Thulin 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para uso na prevenção e/ou no tratamento de surmenage em um mamífero

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
CA2332774A1 (en) * 1998-05-15 1999-11-25 Dov Michaeli Method for the treatment of gastroesophageal reflux disease
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1703403A (zh) * 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂

Also Published As

Publication number Publication date
HK1075833A1 (en) 2005-12-30
CN1662235A (zh) 2005-08-31
DE60320990D1 (de) 2008-06-26
CA2489730A1 (en) 2003-12-31
ATE395059T1 (de) 2008-05-15
EP1513525A1 (en) 2005-03-16
MXPA04012659A (es) 2006-05-25
CY1107954T1 (el) 2013-09-04
SE0201943D0 (sv) 2002-06-20
CA2489730C (en) 2011-11-22
WO2004000316A1 (en) 2003-12-31
ES2304510T3 (es) 2008-10-16
JP2011068669A (ja) 2011-04-07
PL372186A1 (en) 2005-07-11
NZ536559A (en) 2007-08-31
ZA200409908B (en) 2006-08-30
AU2003241585B2 (en) 2009-06-25
EP1513525B1 (en) 2008-05-14
RU2324484C2 (ru) 2008-05-20
JP2006507225A (ja) 2006-03-02
DK1513525T3 (da) 2008-08-11
SI1513525T1 (sl) 2008-08-31
JP4683920B2 (ja) 2011-05-18
IL165138A0 (en) 2005-12-18
BR0311759A (pt) 2005-03-08
IS7654A (is) 2005-01-19
AU2003241585A1 (en) 2004-01-06
NO20050154L (no) 2005-01-11
CN100430056C (zh) 2008-11-05
UA81627C2 (ru) 2008-01-25
RU2005101411A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
ATE301649T1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
IL148157A0 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MY140236A (en) Diarylether compounds useful as opioid receptor antagonists
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
NO20035367D0 (no) Modulatorer av peroksisomproliferatoraktiverte reseptorer (PPAR)
NO20042378L (no) A2B-adenosinreseptorantagonister
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
BR0000486A (pt) Antagonistas do neuropeptìdeo y
WO2003099823A3 (en) 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
SE0303492D0 (sv) New use VII
WO2005060961A3 (en) Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
DE69922918D1 (de) Neuropeptid Y Antagonisten
SE0303490D0 (sv) New use V
TW200626565A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
HK1094159A (en) Use of metabotropic glutamate receptor 5 (mglur5) antagonists for the treatment of gastrointestinal disorders
SE0303419D0 (sv) New use 11